The protection against probes of past tax filings was part of a settlement in which Trump agreed to drop a $10 billion lawsuit he filed against the IRS.
AI is shifting the economics of build-versus-buy as more firms turn to apps created not by software vendors but by code generators such as Claude, Replit, or Cursor.
Kalohexis is working on peptide therapies, including one for obesity that could offer an alternative approach to the GLP-1s that currently dominate the weight loss space.
A surprising deal from Vertex Pharmaceuticals adds to Big Pharma’s acquisitive streak as Crinetics folds into the cystic fibrosis drugmaker. Meanwhile, IPOs and venture capital raises trend upward, but mostly for derisked companies. Plus, FDA decisions slow only slightly as the hunt for a permanent leader drags on.